Study of serum interleukins (IL 13, IL 9, TNF) in asthmatic patients with mite allergy

Asthma is a problem of a genetic inflammatory disease of the respiratory tract-airways in which clinical disease progression is influenced by environmental factors. Chronic airway inflammation, usually with eosinophil infiltration, is one of the hallmarks of asthma. Most asthmatics can be successfully treated with conventional medicine according to their severity, but in certain extreme cases, even with prolonged treatment, asthma remains uncontrolled, which is known as'refractory asthma. A new biologicbased therapy strategy for severe r efractory asthma has been created based on knowledge of the molecular pathways of airway inflammation in asthma produced by enhanced Th2-type responses, eosinophil activation, and allergic reactions. The first biological preparation approved to treat asthma was humanized anti-human IgE antibody (anti-IgE; omalizumab). Treatment with anti-IgE (anti-IgE therapy) has been recognised as a new therapeutic option for severe allergic asthma, IL in adults since 2009 and children since 2012, based on clinical evidence, and has been demonstrated to have a 60% effectiveness rate. The TH2 cytokine family's interleukin (IL)-9 and IL-13 have recently been suggested as a key component in determining mucosal immunity and susceptibility to atopic asthma. TNF- is a key player in the establishment of the Th2 cell response to allergens ingested.